Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Sunshine Biopharma (SBFMW) over the last 5 years, with Q1 2025 value amounting to $2.7 million.

  • Sunshine Biopharma's Shares Outstanding (Diluted Average) rose 32152.67% to $2.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.7 million, marking a year-over-year increase of 32152.67%. This contributed to the annual value of $701749.0 for FY2024, which is 537172.71% up from last year.
  • Per Sunshine Biopharma's latest filing, its Shares Outstanding (Diluted Average) stood at $2.7 million for Q1 2025, which was up 32152.67% from $701749.0 recorded in Q4 2024.
  • In the past 5 years, Sunshine Biopharma's Shares Outstanding (Diluted Average) ranged from a high of $25.7 million in Q3 2023 and a low of $12825.0 during Q4 2023
  • In the last 5 years, Sunshine Biopharma's Shares Outstanding (Diluted Average) had a median value of $4.0 million in 2022 and averaged $9.4 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Shares Outstanding (Diluted Average) crashed by 9991.55% in 2023, and later skyrocketed by 537172.71% in 2024.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Shares Outstanding (Diluted Average) stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then crashed by 99.92% to $12825.0 in 2023, then skyrocketed by 5371.73% to $701749.0 in 2024, then surged by 285.22% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q1 2025, $701749.0 for Q4 2024, and $641310.0 during Q1 2024.